Association Between the MTHFR C677T Polymorphism and Breast Cancer Risk: A Meta‐Analysis of 23 Case–Control Studies
Wanjun Yan,Yafei Zhang,Enfa Zhao,Shuqun Zhang
DOI: https://doi.org/10.1111/tbj.12639
2016-01-01
Abstract:To the Editor: Breast cancer is the most common cancer in women and the incidence has increased in recent years worldwide (1). The mechanism of breast carcinogenesis is still not fully understood. Evidence suggests that susceptibility genes combining with environmental factors may be important in the development of cancer (2). Although there are some well-established risk factors identified for breast cancer (3,4), unfortunately, the mechanisms have not been clearly identified. The clinical features of human Breast cancer are characterized by a considerable heterogeneity. Methylenetetrahydrofolate reductase (MTHFR) is one of the enzymes involved in folate metabolism. MTHFR catalyzes the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate and directs the flux of intracellular folate toward the conversion of homocysteine to methionine at the expense of nucleotide synthesis (5). Folate deficiency has been shown to induce DNA damage through uracil misincorporation into DNA during replication, leading to an increased risk of DNA double-strand breaks during DNA excision repair and subsequent genetic instability (6). It is reported that the minor alleles of one common single nucleotide polymorphisms of MTHFR gene, C677T is in exon 4 at nucleotide 677, which is associated with the decrease in MTHFR activity and increased the level of homocysteine and altered the distribution of folate, has been related to the reduced activity of this enzyme (7). Epidemiologic studies have indicated that folate deficiency may be related to development of several cancers, including breast cancer (8). A number of studies indicate that C677T polymorphisms in the MTHFR gene were involved in the etiology of breast cancer among the total population (9). However, the results from those studies remain conflicting. To shed some light on these controversial results, as well as to decrease the uncertainty of the effect size of estimated risk, a meta-analysis of all available studies relating the C677T polymorphisms of the MTHFR gene to the risk of developing breast cancer was carried out. The present meta-analysis, including 23 studies with 6,564 breast cancer cases and 7,801 case-free controls, explored the association between MTHFR C677T gene polymorphisms and breast cancer risk. The results showed a significant association between MTHFR C677T polymorphism and breast cancer risk when all studies were pooled into the meta-analysis, indicating that the MTHFR 677T allele is a low-penetrance risk factor for developing breastcancer. The overall association of the C677T allele T and breast cancer risk generated an OR of 1.07 (23 studies), whereas among Asians and Caucasians, the ORs were 1.03 (sixteen studies) and 1.13 (seven studies), respectively. The overall OR does not reflect a weighted average of OR, because the number of studies with Asians and Caucasians was not complementary to the total number of studies. Some limitations in this meta-analysis must be addressed. First, this meta-analysis was based on pooled data and no individual data was available; thus, we could not assess the risk of breast cancer according to stratification of age, environment factors, and other risk factors of cancer. Second, small study effect, in which effects reported in small studies are larger, could not be avoided in that some studies were of a relative small size (<2.00). Moreover, further large scale multicenter studies with more detailed individual data, with different environmental background are warranted to further validated Address correspondence and reprint requests to: Shuqun Zhang, Department of Oncology, The Second Affiliated Hospital, Xi’an Jiaotong University, 157 Xiwu Rd., Ixan, Shaanxi 710004, China, or e-mail: zhangshuqun1971@ aliyun.com